![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2022
Anzahl der Publikationen: 5
2022
Zierold, Sarah; Akcetin, Larissa Semra; Gresser, Eva; Maier, Anna Marie; König, Alexander; Kramer, Rafaela; Theurich, Sebastian; Tomsitz, Dirk; Erdmann, Michael; French, Lars E.; Rudelius, Martina und Heinzerling, Lucie 
ORCID: https://orcid.org/0000-0001-5718-3643
(2022):
Checkpoint-inhibitor induced Polyserositis with Edema.
In: Cancer Immunology Immunotherapy, Bd. 71, Nr. 12: S. 3087-3092
[PDF, 658kB]
ORCID: https://orcid.org/0000-0001-5718-3643
(2022):
Checkpoint-inhibitor induced Polyserositis with Edema.
In: Cancer Immunology Immunotherapy, Bd. 71, Nr. 12: S. 3087-3092
[PDF, 658kB]
Schulz, Thomas U.; Zierold, Sarah; Sachse, Michael M.; Pesch, Giulia; Tomsitz, Dirk; Schilbach, Katharina; Kahler, Katharina C.; French, Lars E. und Heinzerling, Lucie
(2022):
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases.
In: Data in Brief, Bd. 45, 108676
[PDF, 312kB]
Tomsitz, Dirk; Schlaak, Max; Zierold, Sarah; Pesch, Giulia; Schulz, Thomas U.; Müller, Genoveva; Zecha, Christine; French, Lars E. und Heinzerling, Lucie
(2022):
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma.
In: Cancers, Bd. 14, Nr. 13
[PDF, 634kB]
Cartun, Zachary; Kunz, Wolfgang G.; Heinzerling, Lucie; Tomsitz, Dirk; Guertler, Anne; Westphalen, C. Benedikt; Ricke, Jens; Weir, William; Unterrainer, Marcus und Mehrens, Dirk
(2022):
Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma.
In: JAMA Dermatology, Bd. 158, Nr. 12: S. 1387-1393
Schulz, Thomas U.; Zierold, Sarah; Sachse, Michael M.; Pesch, Giulia; Tomsitz, Dirk; Schilbach, Katharina; Kaehler, Katharina C.; French, Lars E. und Heinzerling, Lucie
(2022):
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
In: European Journal of Cancer, Bd. 176: S. 88-99